Clinical Trials

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05408845 2026-04-03

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06486883 2026-04-02

PONTIAC

200 enrolled

Advanced Breast Cancer

NCT07371585 2026-03-27

TOP-REAL

300 enrolled

Breast Neoplasms

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

197 enrolled

Colorectal Neoplasms

NCT07069712 2026-03-10

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

100 enrolled

Stomach Neoplasms

NCT06750484 2026-02-27

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

40 enrolled

Breast Cancer Metastatic

NCT04379596 2026-02-23

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06058988 2026-02-23

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

30 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT07428044 2026-02-23

HERCULES

14 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07407465 2026-02-17

CHIMERA

42 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

50 enrolled

Breast Neoplasms

NCT06630130 2025-12-15

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

50 enrolled

Stomach Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT05982678 2025-11-26

ANISE

72 enrolled

HER2-positive Breast Cancer

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT04553770 2025-11-10

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

88 enrolled

Breast Neoplasms

NCT06533826 2025-10-24

TRADE DXd

357 enrolled

Breast Neoplasms

NCT06271837 2025-10-22

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

175 enrolled

Breast Neoplasms

NCT05795101 2025-09-19

TRUDI

63 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT06172127 2025-07-29

DEMETHER

165 enrolled

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT06832202 2025-06-15

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

50 enrolled

HER2-low Hormone Receptor Positive Breast Cancer

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT05965479 2024-11-12

DECIPHER

25 enrolled